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Abstract
To study the efficiency of maintaining the reduced tissue environment via pre-treatment with natural antioxidant resveratrol in stem cell
therapy, we pre-treated male Sprague-Dawley rats with resveratrol (2.5 mg/kg/day gavaged for 2 weeks). After occlusion of the left ante-
rior descending coronary artery (LAD), adult cardiac stem cells stably expressing EGFP were injected into the border zone of the
myocardium. One week after the LAD occlusion, the cardiac reduced environment was confirmed in resveratrol-treated rat hearts by the
enhanced expression of nuclear factor-E2-related factor-2 (Nrf2) and redox effector factor-1 (Ref-1). In concert, cardiac functional
parameters (left ventricular ejection fraction and fractional shortening) were significantly improved. The improvement of cardiac func-
tion was accompanied by the enhanced stem cell survival and proliferation as demonstrated by the expression of cell proliferation
marker Ki67 and differentiation of stem cells towards the regeneration of the myocardium as demonstrated by the enhanced expression
of EGFP 28 days after LAD occlusion in the resveratrol-treated hearts. Our results demonstrate that resveratrol maintained a reduced
tissue environment by overexpressing Nrf2 and Ref-1 in rats resulting in an enhancement of the cardiac regeneration of the adult car-
diac stem cells as demonstrated by increased cell survival and differentiation leading to cardiac function.
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Introduction
Although the results of adult and embryonic stem cell therapy for
the infracted myocardium have yielded promising results for the
enhanced regeneration of myocardial tissue leading to improved
ventricular function [1–3], the effectiveness of stem cell therapy is
often blurred from the non-survival of the stem cells due to the
oxidative stress in the normal tissue [4]. In recent years, several
attempts have been made for the enhancement of the survival and
proliferation of stem cells in conjunction with the stem cell ther-
apy. Overexpression of cardiac survival protein Pim-1 in cardiac
progenitor cells (CPCs) has yielded promising results as demon-
strated by the enhanced proliferation and functional improvement
relative to control progenitor cells after myocardial infarction [5].
In another study, intramyocardial injection of hepatocyte growth
factor stimulated resident CPCs and potentiated cardiomyocyte
regeneration after myocardial infarction by promoting the prolifer-
ation and survival of CPCs [6]. Another related study with
lipopolysaccharide preconditioning of mesenchymal stem cells
before the transplantation surgery, resulted in superior neovascu-
larization resulting in the recovery of cardiac function [7].
Simvastatin improved the efficacy of stem cell in the infracted
myocardium. Interestingly, reduced oxidative environment and
inflammatory response was noticed in the infracted regions of the
animals treated with simvastatin and stem cells [8].
Based on these previously published results, we suggested
that a reduction of the oxidative stress in the myocardium could
improve the results the stem cell therapy. In this study, we exam-
ined the effect of resveratrol on the modification of adult cardiac
stem cell therapy in the rats. This study is unique in that we used
resveratrol as nutrient to alter the oxidative environment of the
myocardium during the stem cell therapy. Our results show that
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maintaining a reduced tissue environment with resveratrol in rat
hearts indeed resulted in the regeneration of infracted heart by
adult cardiac stem cells as shown by improved cell survival, dif-
ferentiation cardiac function.
Stem cell therapy
Sprague-Dawley male rats weighing between 250 and 300 g were
fed ad libitum regular rat chow with free access to water until the
experimental procedure. All animals used in this study received
humane care in compliance with the Animal Welfare Act and other
federal statutes and regulations relating to animals and experi-
ments involving animals and adheres to principles stated in the
Guide for the Care and Use of Laboratory Animals, NRC
Publication, 1996 edition. The rats were randomly assigned to
one of the three groups: (i ) left anterior descending coronary
artery (LAD) occlusion in control group, (ii ) LAD occlusion and
stem cell treatment in control group and (iii ) LAD occlusion and
stem cell treatment in resveratrol- (2.5 mg/kg) treated group. The
rats were anesthetized with ketamine (100 mg/kg) / xylazine 
(10 mg/kg, ip) in combination with buprenorphine (0.5–2.5 mg/kg,
s/c, bd), intubated and ventilated at a rate of 70 breaths/min. 
A left lateral thoracotomy was performed under painless and
aseptic conditions. After the chest was opened, the pericardium
was cut. A 6–0 polypropylene suture was passed under the LAD
at the level of the left atrial appendage. Myocardial ischemia was
produced by permanently occluding the LAD. Then stem cells
were delivered directly on the myocardium into the bordering
regions of ischemia in the second (control) and the third (resver-
atrol-treated) group. The injection needle was introduced 1 mm
into the myocardium at an angle (10–20) in a cranial direction.
After completion of all the surgical procedures, the chest was
closed with 4–0 nylon sutures and the ventilation rate was
reduced to 50 breaths/min. till the spontaneous respiration starts.
The rats were then extubated and kept in a temperature-
controlled environment to prevent hypothermia where the rats were
continuously monitored. Buprenorphine (0.1 mg/kg s.c.) was
administered as an analgesic and gentamycin (1 mg/kg) were
used as antibiotic to prevent post-surgical infections. After 28 days
of surgery, rats were sedated using isoflurene (3%, inhaled),
shaved and placed on a heated pad. Ultrasound gel was spread
over the pericardial region, and ultrasound biomicroscope (Vevo
770, Visual-Sonics, Inc., Toronto, ON, Canada). Transthoracic 
M-mode echocardiography were performed with a Vevo 770
ultrasound system (Agilent Technologies, Andover, MA, USA)
equipped with a 25 MHz transducer as described by us earlier 
to visualize the left ventricle. with a 25 MHz transducer was used
to visualize the left ventricle. The left ventricle was analysed in
apical, parasternal long axis, and parasternal short axis views for
left ventricular inner diameters (LVIDs) both in systole and dias-
tole, and LV functional parameters such as ejection fraction (EF),
fractional shortening (FS) and cardiac output (CO). Two-dimen-
sional directed M-mode images of the LV short axis were taken
just below the level of the papillary muscles to analyse ventricular
wall thickness and chamber diameter. All left ventricular parame-
ters were measured according to the modified American Society
of Echocardiography recommended guidelines. All measurements
from different animals were averaged and represented as men-
tioned earlier [9]. After performing M-mode echocardiography,
rats were anesthetized with sodium pentobarbital (80 mg/kg, i.p.),
(Abbott Laboratories, North Chicago, IL, USA) and with the anti-
coagulant heparin sodium (500 IU/kg. i.v.) (Elkins-Sinn, Inc.,
Cherry Hill, NJ, USA). After ensuring sufficient depth of anaesthesia,
thoracotomy was performed, hearts were isolated and perfused in
the retrograde Langendorff mode at 37C at a constant perfusion
pressure of 100 cm of water (10 kPa) for a 10 min. washout
period. The perfusion buffer used in this study consisted of a
modified Krebs–Henseleit bicarbonate buffer (in mM: sodium
chloride 118, potassium chloride 4.7, calcium chloride 1.7,
sodium bicarbonate 25, potassium biphosphate 0.36, magnesium
sulphate 1.2 and glucose 10). The hearts were then removed from
the apparatus, and frozen with O.C.T. compound, and stored at
–20C. All values were expressed as the mean  S.E.M. Analysis
of variance test followed by Bonferoni’s correction was first car-
ried out to test for any differences between the mean values of all
groups. If differences were established, the values of the treated
groups were compared with those of the control group by a modified
t-test. The results were considered significant if P  0.05.
Heart tissue samples collected at the end of experiments were
frozen with Tissue-Tek embedding medium optimal culture tem-
perature O.C.T. compound and subjected to cryo-sectioning. The
obtained specimens (5 m cuts) were processed for immunoflu-
orescence analysis as described previously [10]. The primary 
antibodies such as GFP (Cell Signaling Technology, Beverly, MA,
USA; 1:100 dilution), c-kit (Cell Signaling Technology; 1:100 dilu-
tion), nuclear factor-E2-related factor-2 (Nrf2; Cell Signaling
Technology; 1:50 dilution), redox effector factor-1 (Ref-1; Santa
Cruz Biotechnology, Santa Cruz, CA, USA; 1:50 dilution), Ki67
(Santa Cruz Biotechnology; 1:50 dilution) and cardiac myosin
(Abcam, Cambridge, MA, USA; 1:100 dilution) were incubated
overnight at 4C. This was followed by incubation with Alexa-
Fluor® fluorochrome-conjugated secondary antibodies (Molecular
Probes; 1:500 dilution), and the nuclear staining were performed
with Topro-3-iodide (Molecular Probes, Carlsbad, CA, USA; 1:500
dilution). The slides were washed and covered with mounting
medium, and examined under a fluorescence microscope.
Confocal microscopic images were obtained using Zeiss LSM 510
(Thornwood, NY, USA) confocal laser scanning microscope by
simultaneous recording in the 488 , 530  and/or 560  channels
as appropriate. We monitored the nuclear expression of Nrf2 and
Ref-1 7 days and 28 days after LAD occlusion using confocal
immunofluorescence microscopy. Our results show that the
nuclear expression of Nrf2 and Ref-1 were significantly increased
7 days after LAD occlusion in resveratrol-treated myocardium rel-
ative to control (Table 1). However, the nuclear expression of Nrf2
and Ref-1 were not significantly increased 28 days after LAD
occlusion (data not shown).
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Regeneration of myocardium 
28 days after myocardial 
infarction
Cellular proliferation was studied by the expression of Ki67 
28 days after LAD occlusion, and our results show that Ki67
staining was remarkably increased in resveratrol-treated
myocardium compared to control hearts (Table 1). Cardiac
regeneration was studied by staining the cardiac tissue section
with GFP. Quantification of GFP staining 28 days after LAD occlu-
sion indicate that GFP staining was remarkably increased in
resveratrol-treated myocardium compared to control hearts.
Confocal microscopic images showed the significant enhance-
ment of c-kit cells 28 days after myocardial infarction in resver-
atrol-treated samples (Fig. 1A), and the co-expression of SDF-1
and GFP in resveratrol-treated hearts (Fig. 1B) leading to the
regeneration of the myocardium in the resveratrol-treated heart
(Fig. 1C). M-mode echocardiogram of rats recorded at 28 days
after survival surgery reveal that resveratrol treatment enhanced
the cardiac stem cell-mediated improvement in cardiac func-
tional parameters such as LVID in systole, EF, LVID in diastole,
FS and CO (Table 2).
Concluding remarks
Despite the cell-based therapy for cardiac diseases has yielded
promising results for the improvement of cardiac function and
regeneration, the stems cells fail to survive for a prolonged time
for several factors including the persistence of oxidative environ-
ment in the target tissue. In clinical trials for the treatment of acute
and chronic myocardial ischemia, a variety of progenitor cells
including bone marrow-derived progenitor cells, bone marrow-
derived mononuclear circulating progenitor cells, as well as 
skeletal myoblasts have been used [13]. Even though the results
of cell-based therapies are promising, the improvement in cardiac
function and myocardial regeneration has not been satisfactory.
Several modifications including the reduction of oxidative stress
have been made in an attempt to improve the performance of a
cell-based therapy by modifying the cells prior to treatment. We
suggested that the stem cell homing and proliferation could also
be manipulated by modifying the physiological redox environment
by proper nutrition. Thus, we examined the effects of adult cardiac
stem cell therapy in animals treated with a definite dosage of [11]
resveratrol, a polyphenolic compound present in red wine and
grapes, which possesses the ability to enhance myocardial sur-
vival by changing the intracellular oxidative environment into a
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Table 1 Regeneration of infracted myocardium with resveratrol-modified cardiac stem cells
*P  0.05 versus –Resveratrol.
Expression and nuclear 
co-localization
7 days after infarction 28 days after infarction
(Pixel/nuclear co-localization)
–Resveratrol Resveratrol –Resveratrol Resveratrol
Nrf2 500  25 1125  27* 27  5 322  14*
Ref-1 710  21 2350  35* 32  5 375  20*
Ki67 105  20 650  31* 85  5 603  19*
Fig. 1 Co-expression of SDF-1 and GFP in the
resveratrol-treated hearts. (A) Expression of
c-kit (green channel) 28 days after myocar-
dial infarction in resveratrol-treated samples,
where the blue channel shows the nucleus.
(B) Confocal microscopic images of left 
ventricular tissue section showing the
expression of SDF-1 and GFP 28 days after
myocardial infarction in resveratrol-treated
samples. (C) Expression of cardiac stem cell
mediated GFP (green) in the resveratrol-
treated heart.
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reduced environment [12]. We also selected this compound
because of its well-known ability to enhance the antioxidant
defence mechanism [12]. Our results revealed for the first time
that it is possible to maintain a safer niche for the stem cells with
proper nutrition, which could result in enhanced proliferation,
myocardial regeneration and differentiation leading to an
improved cardiac function. To achieve this, we pre-treated the rats
with resveratrol, in a pre-determined dosage of 2.5 mg/kg/day
[11]. Resveratrol has the potential to donate hydrogen or react
with superoxide anion, hydroxyl radicals and lipid peroxyl radicals
[14], and has been shown to modulate antioxidant enzymes
involved in the phase II response such as haem oxygenase 1 [15].
Furthermore, resveratrol has been shown to increase plasma
antioxidant capacity and decrease lipid peroxidation in vivo [16].
In vitro studies show that resveratrol prevents myocardial infarc-
tion by chelating metal ions as well as by directly scavenging free
radicals [17]. Resveratrol induces the activities of catalase and
quinone reductase 1 and reduces the amount of reactive oxygen
species (ROS) generated by menadione in the myocardium of
guinea pigs [18]. Altogether, these results indicate that resveratrol
can suppress pathological oxidative stress in vivo. In this study,
we examined the redox status of the myocardium 7 days after the
survival surgery by monitoring Nrf2, a master gene of the endoge-
nous antioxidant defence system, in the heart. A recent study
showed that redox status in the extracellular compartment regu-
lates intracellular ROS, which play an important role in the activa-
tion of Nrf2 and up-regulation of antioxidant and detoxification
systems in mouse embryonic fibroblasts [19]. Nrf2 plays a critical
role in the protection of the murine heart against pathological car-
diac hypertrophy and heart failure via suppressing oxidative stress
[20] Nrf2 mediated adaptive response has been shown to protect
against superoxide anion-induced oxidative damage [21] and cad-
mium-induced oxidative stress in mouse embryonic fibroblasts
[22]. Because dietary polyphenols including resveratrol are known
to elicit anti-oxidant mechanism via activation of Nrf2 [23], we
studied the activation of Nrf2 as a redox activation marker in our
samples. The nuclear activation of Nrf2 was significantly elevated
in resveratrol-treated rats, and a close association between Nrf2
activation and GEFP stem cells’ localization was noticed. Further,
it is to be noted that endogenous ROS are shown to function as
signalling molecules for myogenic differentiation via regulation of
Nrf2 and glutathione redox [24] Ape1/Ref-1 is a novel redox com-
ponent of signal transduction processes that regulate eukaryotic
gene expression. Ape1/Ref-1 activates several transcription 
factors and facilitates their DNA binding via the reduction of a 
cysteine residue [25]. Three-dimensional molecular structure
modelling and virtual screening show that resveratrol docks into a
druggable pocket of Ref-1 protein [26]. Previously, we have
demonstrated that resveratrol possesses the ability to protect the
cells at lower doses as observed during pharmacological precon-
ditioning of the heart, whereas at higher doses it causes cell death
as found for cancer cells [11]. In the present study, we have found
that Ref-1 activation was significantly increased in resveratrol-
treated hearts.
In conclusion, our results suggest that cell-based therapy in
the ischemic myocardium can be enhanced by nutritional mod-
ification of intracellular redox environment with resveratrol via
enhanced stem cell survival, proliferation and cardiac regener-
ation and function compared to only stem cell treated rat
hearts. The above effects were shown to be mediated through
the ability of resveratrol to enhance the redox potential in the
target organ.
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Table 2 Improvement of cardiac function after resveratrol-modified stem cell therapy
LVID-S: left ventricular internal diameter in systole; LVID-D: left ventricular internal diameter in diastole; EF: ejection fraction; FS: fractional shortening;
CO: cardiac output.
*P  0.05 versus –Resveratrol.
Functional parameters 7 days after infarction 28 days after infarction
–Resveratrol Resveratrol –Resveratrol Resveratrol
LVID-S 5.0  0.1 5.9  0.2 5.5  0.2 6.2  0.3*
LVID-D 6.1  0.2 6.8  0.3 6.0  0.3 7.8  0.2*
EF 38  0.4 42  0.3 40  1.0 60  2.2*
FS 38  2.5 43  2.6 41  3.2 58  4.0*
CO 41  1.8 50  3.4 43  2.3 75  4.1*
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